Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02559973
Other study ID # RB-US-13-0006
Secondary ID
Status Completed
Phase Phase 1
First received September 23, 2015
Last updated January 30, 2017
Start date September 2015
Est. completion date March 2016

Study information

Verified date January 2017
Source Indivior Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-center, randomized, open-label, single-dose, parallel-group study which will enroll and randomize approximately 48 subjects (to achieve 36 completers) with opioid use disorder (OUD) who are seeking treatment for OUD. The study includes both a Residential (Inpatient) and Non-Residential (Outpatient) Period.


Recruitment information / eligibility

Status Completed
Enrollment 47
Est. completion date March 2016
Est. primary completion date February 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Currently meets DSM-5 criteria for moderate or severe opioid use disorder (OUD)

- Is seeking treatment for OUD

- Body mass index: = 18.0 to = 35.0 kg/m^2

- Females: Female individuals of childbearing potential (defined as all women who are not surgically sterile or postmenopausal for at least 1 year prior to informed consent) must have a negative serum pregnancy test prior to enrollment and must agree to use a medically acceptable means of contraception from Screening through at least 6 months after the last dose of Investigational Medicinal Product (IMP).

- Males: Male individuals with female partners of child-bearing potential must agree to use medically acceptable contraception after signing the informed consent form through at least 6 months after the last dose of IMP. Male individuals must also agree not to donate sperm during the study and for 6 months after receiving the last dose of IMP.

- Have a normal electrocardiogram (ECG) or ECG with no clinically significant findings in the opinion of the Investigator or medically qualified sub-investigator at Screening and through pre-dose on Day 1.

- Agree not to take any buprenorphine-containing products, other than those administered for the current study, throughout the duration of the study.

- Willing to adhere to study procedures and provide written informed consent prior to start of any study procedures.

Exclusion Criteria:

- Current diagnosis, other than OUD, requiring chronic opioid treatment.

- Pregnant or lactating females.

- Have an ECG demonstrating a corrected QT interval using Fridericia's calculation (QTcF) > 450 msec in males and QTcF > 470 msec in females upon admission to the residential facility or prior to administration of RBP-6000.

- Currently meet the criteria for diagnosis of moderate or severe substance use disorder, by DSM-5 criteria, for any substances other than opioids, and/or tobacco.

- Had a significant traumatic injury, major surgery, or open biopsy within the 4 weeks prior to signing the informed consent form.

- Used buprenorphine-containing products within the 14 days prior to signing the informed consent form.

- Have a history of suicidal ideation within the 30 days prior to signing the informed consent form or prior to study drug administration

- Have a history or presence of allergic or adverse response (including rash or anaphylaxis) to buprenorphine, naloxone, methadone, or the ATRIGEL Delivery System.

- Individuals who have a positive urine drug screen (UDS) prior to admission to the residential facility for barbiturates, benzodiazepines, buprenorphine, or methadone.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RBP-6000
RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.
SUBOXONE Sublingual Film
Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.

Locations

Country Name City State
United States Vince & Associates Clinical Research Overland Park Kansas

Sponsors (1)

Lead Sponsor Collaborator
Indivior Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area Under the Concentration-Time Curve from Study Day 1 to Day 29 (AUC0-28days) of Buprenorphine Relative bioavailability will be assessed using AUC0-28days. Day 1 to Day 29
Primary Maximum Observed Plasma Concentration (Cmax) of Buprenorphine Relative bioavailability will also be assessed using Cmax Day 1 to Day 57
Secondary Area Under the Concentration-Time Curve from Study Day 1 to Day 29 (AUC0-28days) of Norbuprenorphine Day 1 to Day 29
Secondary Maximum Observed Plasma Concentration (Cmax) of Norbuprenorphine Day 1 to Day 57
Secondary Participants with Treatment-Emergent Adverse Events Day 1 to Day 57
See also
  Status Clinical Trial Phase
Recruiting NCT06021431 - Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT N/A
Completed NCT06266572 - Overcoming Stigma and Improving Outcomes for SUDs Through Education, Engagement, and Empowerment Phase 1
Recruiting NCT05037682 - Pain and Opioid Management in Older Adults N/A
Completed NCT06200740 - Remotely Observed Methadone Evaluation N/A
Not yet recruiting NCT06441604 - Extended-release Buprenorphine as a Novel Low-dose Induction Strategy Phase 2
Recruiting NCT06028126 - Superficial Parasternal Intercostal Plane Block in Cardiac Surgery Trial N/A
Completed NCT02593474 - Medication-Assisted Treatment for Youth With Substance Use Disorders Phase 1
Completed NCT02440256 - Expanded HIV Care in Opioid Substitution Treatment (EHOST) Trial N/A
Completed NCT05587998 - A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users. Phase 1
Terminated NCT04577144 - An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term
Recruiting NCT06001437 - Following Outcomes Remotely Within Addiction Recovery Domains
Recruiting NCT05976646 - Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion Phase 1/Phase 2
Completed NCT05546229 - Assessment of Methadone and Buprenorphine in Interstitial Fluid
Not yet recruiting NCT06104280 - Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment N/A
Not yet recruiting NCT06416020 - Integrating MOUD in African American Community Settings (Better Together) N/A
Recruiting NCT06206291 - Cannabidiol for Opioid Addiction Phase 2
Completed NCT05552040 - START NOW in the Treatment of Opioid Addicted Individuals N/A
Recruiting NCT05459922 - Adjunctive Bright Light Therapy for Opioid Use Disorder N/A
Recruiting NCT05343169 - Community-based Education, Navigation, and Support Intervention for Military Veterans N/A
Recruiting NCT06081985 - Efficacy of Deep Transcranial Magnetic Stimulation in Patients With Opioid Use Disorder N/A